Skip to main content
Clinical Trials/NCT03529344
NCT03529344
Completed
Not Applicable

A 6-week Pilot Study to Investigate the Effects of Protein Hydrolysate From Blue Whiting on Glucose Regulation, Inflammation and Serum Lipids in Elderly Nursing Home Residents From Western Norway

University of Bergen0 sites24 target enrollmentAugust 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Muscle Weakness
Sponsor
University of Bergen
Enrollment
24
Primary Endpoint
Participant compliance
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The elderly population have and increased risk of loss of both muscle mass and function and is therefore recommended a higher protein intake than the healthy adult population. These age-related changes in muscle function may be explained by chronic low-grade inflammation and insulin resistance. Despite the recommendation of a higher protein intake, little is known about how different protein sources may affect the metabolic health in this population. Analysis of amino acid composition show that fish can be a good protein source for humans. Many fish species are today used as feed ingredients, rather than a protein source for humans. A few studies conducted in humans and rats show that proteins from fish may improve glucose tolerance, reduce inflammation and improve lipid metabolism, indicating that proteins from fish may not only serve as a valuable nutrient but could also hold specific health promoting properties.

The present study will investigate the effects of a protein hydrolysate from blue whiting, a fish species normally used to produce fish meal for aquaculture industry, on glucose homeostasis, inflammation and serum lipids in elderly nursing home residents.

Detailed Description

Participants receive 6g per day of protein hydrolysate from blue whiting as protein powder mixed with a non-caloric juice for 6 weeks.

Registry
clinicaltrials.gov
Start Date
August 2016
End Date
December 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Oddrun Anita Gudbrandsen

Principal Investigator

University of Bergen

Eligibility Criteria

Inclusion Criteria

  • \>60 years
  • both genders
  • nursing home resident

Exclusion Criteria

  • life expectancy \< 6 months
  • severe cognitive impairment
  • allergies towards fish, milk, egg
  • weight loss \>5% last 3 months

Outcomes

Primary Outcomes

Participant compliance

Time Frame: 6 weeks

Investigate the participant compliance based daily registrations by nursing home staff

Participant dropout rate

Time Frame: 6 weeks

Number of participants that completed the intervention period

Secondary Outcomes

  • Insulin(6 weeks)
  • Monocyte chemoattractant protein-1 in serum(6 weeks)
  • Glucose regulation(6 weeks)
  • C-reactive protein in serum(6 weeks)
  • Interleukin-6 in serum(6 weeks)

Similar Trials